Any feedback?
Literature summary extracted from
- Actions of ethnobotanically selected Cree anti-diabetic plants on human cytochrome P450 isoforms and flavin-containing monooxygenase 3 (2009), J. Ethnopharmacol., 126, 119-126.
Application
| EC Number | Application | Comment | Organism |
|---|---|---|---|
| 1.14.14.1 | biotechnology | most Cree anti-diabetic plant ethanolic extracts have the potential to affect CYP2C- and 3A4-mediated metabolism, and have the potential to affect the bioavailability and pharmacokinetics of conventional and traditional medicines during concomitant use, thus there is a potential risk of interactions if these traditional medicines are used with conventional therapeutic products, but several extracts may also have the potential to pharmacoenhance the activity of some medicines | Homo sapiens |
Cloned(Commentary)
| EC Number | Cloned (Comment) | Organism |
|---|---|---|
| 1.14.14.1 | microsomes derived from baculovirus infected insect cells expressing CYP1A2 | Homo sapiens |
| 1.14.14.1 | microsomes derived from baculovirus infected insect cells expressing CYP2B6 | Homo sapiens |
| 1.14.14.1 | microsomes derived from baculovirus infected insect cells expressing CYP2C8 | Homo sapiens |
| 1.14.14.1 | microsomes derived from baculovirus infected insect cells expressing CYP2C9, CYP2C19, CYP2E1, CYP3A4, or CYP19 | Homo sapiens |
| 1.14.14.1 | microsomes derived from baculovirus infected insect cells expressing CYP2D6 | Homo sapiens |
| 1.14.14.1 | microsomes derived from baculovirus infected insect cells expressing CYP3A5 | Homo sapiens |
| 1.14.14.1 | microsomes derived from baculovirus infected insect cells expressing CYP3A7 | Homo sapiens |
Inhibitors
| EC Number | Inhibitors | Comment | Organism | Structure |
|---|---|---|---|---|
| 1.14.14.1 | bifonazole | CYP19 | Homo sapiens |  |
| 1.14.14.1 | diethyldithiocarbamate | CYP2E1 | Homo sapiens | |
| 1.14.14.1 | furafylline | - |
Homo sapiens | |
| 1.14.14.1 | ketoconazole | CYP3A4 | Homo sapiens | |
| 1.14.14.1 | additional information | inhibition by Cree anti-diabetic plant ethanolic extracts; inhibition by Cree anti-diabetic plant ethanolic extracts. Extracts from Rhododendron groenlandicum, Sorbus decora, and Kalmia angustifolia are identified as having strong inhibition towards many CYP isoforms. Most inhibitory extracts towards CYP2B6-mediated metabolism are Juniperus communis followed by Rhododendron groenlandicum and Rhododendron tomentosum; inhibition by Cree anti-diabetic plant ethanolic extracts. Extracts from Rhododendron groenlandicum, Sorbus decora, and Kalmia angustifolia are identified as having strong inhibition towards many CYP isoforms. Most inhibitory extracts towards CYP2C9-mediated metabolism are Lycopodium clavatum followed by Sorbus decora and Juniperus communis. Most inhibitory extracts towards CYP2C19-mediated metabolism are Lycopodium clavatum followed by Juniperus communis and Larix laricina. Most inhibitory extracts towards CYP2E1-mediated metabolism are Kalmia angustifolia followed by Gaultheria hispidula and Rhododendron groenlandicum. Most inhibitory extracts towards CYP19-mediated metabolism ware Sorbus decora followed by Kalmia angustifolia and Abies balsamea. Most inhibitory extracts towards CYP3A4-mediated dibenzylfluorescein metabolism are Pinus banksiana followed by Picea mariana and Salix planifolia. Most inhibitory extracts towards CYP3A4-mediated testosterone metabolism are Larix laricina followed by Juniperus communis and Rhododendron groenlandicum. Gaultheria hispidula, Juniperus communis, Larix laricina, Picea mariana, Rhododendron tomentosum, Salix planifolia and Sarracenia purpurea, have diverging inhibition towards the two substrates dibenzylfluorescein and testosterone; inhibition by Cree anti-diabetic plant ethanolic extracts. Most inhibitory extracts towards CYP1A2-mediated metabolism are Rhododendron groenlandicum followed by Pinus banksiana and Picea mariana; inhibition by Cree anti-diabetic plant ethanolic extracts. Most inhibitory extracts towards CYP2C8-mediated metabolism are Sorbus decora followed by Lycopodium clavatum and Rhododendron tomentosum; inhibition by Cree anti-diabetic plant ethanolic extracts. Most inhibitory extracts towards CYP2D6-mediated metabolism are Rhododendron groenlandicum followed by Sarracenia purpurea and Kalmia angustifolia; inhibition by Cree anti-diabetic plant ethanolic extracts. Most inhibitory extracts towards CYPMost inhibitory extracts towards CYP3A5-mediated metabolism are Sorbus decora followed by Rhododendron groenlandicum and Kalmia angustifolia | Homo sapiens | |
| 1.14.14.1 | quinidine | - |
Homo sapiens | |
| 1.14.14.1 | sulfaphenazole | CYP2C9 | Homo sapiens | |
| 1.14.14.1 | tranylcypromine | CYP2C19 | Homo sapiens | |
Organism
| EC Number | Organism | UniProt | Comment | Textmining |
|---|---|---|---|---|
| 1.14.14.1 | Homo sapiens | - |
- |
- |
| 1.14.14.1 | Homo sapiens | P05177 | - |
- |
| 1.14.14.1 | Homo sapiens | P10632 | - |
- |
| 1.14.14.1 | Homo sapiens | P10635 | - |
- |
| 1.14.14.1 | Homo sapiens | P20813 | - |
- |
| 1.14.14.1 | Homo sapiens | P20815 | - |
- |
| 1.14.14.1 | Homo sapiens | P24462 | - |
- |
Substrates and Products (Substrate)
| EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|---|
| 1.14.14.1 | 3-cyano-7-ethoxycoumarin + [reduced NADPH-hemoprotein reductase] + O2 | - |
Homo sapiens | ? | - |
? | |
| 1.14.14.1 | 3-cyano-7-ethoxycoumarin + [reduced NADPH-hemoprotein reductase] + O2 | CYP2C19 | Homo sapiens | ? | - |
? | |
| 1.14.14.1 | 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin + [reduced NADPH-hemoprotein reductase] + O2 | - |
Homo sapiens | ? | - |
? | |
| 1.14.14.1 | 7-methoxy-4-(trifluoromethyl)-coumarin + [reduced NADPH-hemoprotein reductase] + O2 | - |
Homo sapiens | ? | - |
? | |
| 1.14.14.1 | 7-methoxy-4-(trifluoromethyl)-coumarin + [reduced NADPH-hemoprotein reductase] + O2 | CYP2C9, CYP2E1 | Homo sapiens | ? | - |
? | |
| 1.14.14.1 | dibenzylfluorescein + [reduced NADPH-hemoprotein reductase] + O2 | - |
Homo sapiens | ? | - |
? | |
| 1.14.14.1 | dibenzylfluorescein + [reduced NADPH-hemoprotein reductase] + O2 | CYP3A4, CYP19 | Homo sapiens | ? | - |
? | |
| 1.14.14.1 | testosterone + [reduced NADPH-hemoprotein reductase] + O2 | CYP3A4 | Homo sapiens | ? | - |
? | |
Synonyms
| EC Number | Synonyms | Comment | Organism |
|---|---|---|---|
| 1.14.14.1 | CYP19 | - |
Homo sapiens |
| 1.14.14.1 | CYP1A2 | - |
Homo sapiens |
| 1.14.14.1 | CYP2B6 | - |
Homo sapiens |
| 1.14.14.1 | CYP2C19 | - |
Homo sapiens |
| 1.14.14.1 | CYP2C8 | - |
Homo sapiens |
| 1.14.14.1 | CYP2C9 | - |
Homo sapiens |
| 1.14.14.1 | CYP2D6 | - |
Homo sapiens |
| 1.14.14.1 | CYP2E1 | - |
Homo sapiens |
| 1.14.14.1 | CYP3A4 | - |
Homo sapiens |
| 1.14.14.1 | CYP3A5 | - |
Homo sapiens |
| 1.14.14.1 | CYP3A7 | - |
Homo sapiens |
| 1.14.14.1 | FMO3 | - |
Homo sapiens |
| 1.14.14.1 | monooxygenase 3 | - |
Homo sapiens |
Cofactor
| EC Number | Cofactor | Comment | Organism | Structure |
|---|---|---|---|---|
| 1.14.14.1 | NADPH | - |
Homo sapiens | |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
